PMV Pharma presents updated Phase 2 rezatapopt data at ENA symposium

PMVP•2026-11-04

PMV Pharmaceuticals will present pivotal Phase 2 rezatapopt trial results at ENA 2026 in Barcelona on November 20, 2026.

1. Planned presentation

PMV Pharmaceuticals will present pivotal Phase 2 rezatapopt trial results at ENA 2026 in Barcelona on November 20, 2026. Alison M. Schram of Memorial Sloan Kettering Cancer Center will deliver the late-breaking oral presentation at 15:00 CET.

PMV Pharma presents updated Phase 2 rezatapopt data at ENA symposium

1. Planned presentation

Related News

Melco Resorts Q3 2026 net income attributable to company falls to USD 34,000

Eagle Materials publishes fiscal 2027 second-quarter earnings presentation

Firefly Aerospace: B. Riley cuts target price to $40 from $50

Gold gains 3% as dollar slides after Democratic midterm gains

B. Riley cuts Upstart Holdings target price to $42 from $54